Overview
We held 1st China Pharma IP Summit 2016 on 17-18, November last year and confirmed more than 190 attendees from government agencies, in-house IP counsel, IP law firms, agencies and solution providers. The development of pharmaceutical industry heavily relies on their IP strategies, and this year pharmaceutical IP protection in China is drawing more attentions than before. Firstly, on 12th May 2017, the China Food and Drug Administration issued a proposal ( called 2017 Policy Notice No.55), which proposes to establish the patent linkage and amend the regulatory data protection regime. In the Notice No.55, it indicates the procedures of patent linkage and changes of regulatory data protection. Secondly, China is studying the drug patent extension reform, and the result may come out within this year. Additionally, the SIPO is amending PATENT LAW OF THE PEOPLE'S REPUBLIC OF CHINA and the new amendments to SIPO's Guidelines for Patent Examination has been effective since 1st April, 2017.
Based on above we will launch 2nd China Pharma IP Summit 2017 on 7th -8th December this year in Shanghai, and continue to provide a networking platform for industry peers.
Through the event, you can:
1. Follow updated policies in China, including patent linkage, regulatory data protection, patent extension reform, and the changes of Patent Law and Guidelines for Patent Examination.
2. Understand the latest examination standards and litigation proceedings in US and Europe
3. Learn excellent IP management cases
4. Meet you client fact to face and interacts with industry peers
The participants are mainly from pharma companies, biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!
Thanks again for your attention and looking forward to your participation!
|
Agenda:
|
|
DAY 1 Morning
|
|
|
0730
|
Registration Open
|
|
|
0840
|
Opening Remark
Day1 Chairman: Tony Chen, Partner, Jones Day
|
|
|
0850
|
Managing Global IP Strategy & Team--Practical Insights
John D. Conway, Senior Vice President and Global Head of Intellectual Property, Sanofi
|
|
|
0925
|
505(b)(2) NDAs v. ANDAs: Case Studies and Implications for Patent Portfolio Development and US Litigation
Christopher T. Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP
|
|
|
1000
|
Coffee Break
|
|
|
1035
|
Interpretation of Specific Pharmaceutical Intellectual Property Policies in China
Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association
|
|
|
1110
|
Drug Patent Extension Reform in China--From a Perspective of China Innovative Drugs Status
Li Chen, Co-founder and CEO, Hua Medicine (Shanghai) Ltd
|
|
1145
|
Panel Discussion: Rules For The Implementation of Patent Linkage in China
Modertor:
Tony Chen, Partner, Jones Day
Panelists:
Randall Rader, Former Chief Judge, the United States Court of Appeals for the Federal Circuit
Chen Li, Co-founder and CEO, Hua Medicine (Shanghai) Ltd
Cheng Yongshun, Director, Beijing Intellectual Property Institute (Former Senior Judge and the
Deputy Presiding Judge of the IP Division of Beijing High People’s Court)
|
|
|
1240
|
Lunch Buffet
|
|
|
DAY 1 Afternoon
|
|
|
1400
|
Patent Acquisition: Due Diligence Issues
Alyson Wooten, Senior Associate, Kilpatrick Townsend & Stockton LLP
|
|
|
1435
|
Patent Invalidation Case Study
Chen Zhefeng, Senior Patent Attorney, Prosecution Department of Chemistry, Shanghai Patent & Trademark Law Office, LLC
|
|
|
1510
|
Coffee Break
|
|
|
1545
|
Topic is Confirming
Wu Li, AnJie Law Firm
|
|
|
1620
|
Regulatory Data Protection Regime Changes in China and Impacts
Chen Bing, Associate Dean, China Food and Drug Administration Insititute of Executive Development;Deputy Director of Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association
|
|
|
1655
|
Panel Discussion: Hotspot Issues of Pharmaceutical Patent and What Can We Learn?
Moderator:
Heather Lin, Senior Partner and Patent Attorney, NTD Intellectual Property Attorneys
Panelists:
Alvin Deng, Head of Intellectual Property, Novozymes China
Li Renjiu, Senior Patent Director, Luye Pharma Group Ltd
Christopher Shaowei, Senior Partner, NTD Patent & Trademark Agency
Ge Yongqi, Deputy Director of The First
|
|
|
1820
|
End of Day 1
|
|
|
DAY 2 Morning
|
|
|
0830
|
Chairman Opening Remark
Wang Ningling, Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP
|
|
|
0845
|
The Latest Developments of Patenting Pharmaceutical and Biotechnological Inventions at the EPO
The speaker will build up on his last year’s presentation and update more specifically on new case law and practice as regards patentability requirements for pharmaceuticals and biotechnological inventions, including the recent changes to the implementing regulations in respect of plant patenting. He will also update on other EPO developments such as the new opposition practice, IP5 developments (global dossier, extension of validation states and PPH)
Dieter Tzschoppe, Director Operations for Biotechnology / Pure and Applied Organic Chemistry, European Patent Office
|
|
|
0920
|
Generic Product Launches - Preparing Strategies Which Address Global IP and Regulatory Issues
Yehudah Livneh, Strategic IP consultant; Former General Patent Counsel and VP Corporate IP and Legislative Affairs at Teva Pharmaceuticals
|
|
|
0955
|
Patent Litigation in Europe With Emphasis on Germany Including A Case Study (Zhejiang Medicines Co., Ltd. vs. Kaneka "Coenzyme Q10)
Dr. Ute Kilger and Dr. Markus Engelhard, BOEHMERT & BOEHMERT
|
|
|
1030
|
Coffee Break
|
|
|
1110
|
State of Play of Biosimilars in the Europe
●History of development and registration
●Dealing with exclusivity / patent litigation
●Marketing strategies
Christof Bull, Associate General Patent Counsel, UCB Biopharma
|
|
|
1145
|
Panel Discussion:The US Supreme Court Ruling on Amgen vs. Sandoz Case And What Developers Need To Know?
Moderator:
Wang Ningling, Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP
Panelists:
Dipak Mundra, Partner, LexOrbis
Joo Mee Kim, Member, Rothwell Figg
Stephen Auten, Partner, Taft Stettinius & Hollister LLP
Yang Yieyie, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
|
|
|
1230
|
Lunch Buffet
|
|
|
DAY 2 Afternoon
|
|
|
1400
|
The Fact Investigating And Evidence Determination in Pharmaceutical Patent Infringement Lawsuits
Yongqi Ge, Deputy Director of The First Administrative Proceedings Division, Patent Reexamination Board of SIPO
|
|
|
1435
|
Patent Management Case Study---- From R&D To Launch
Xu Shuwen, Legal Director, Guangzhou Baiyun Mountain Pharmaceutical Factory
|
|
|
1510
|
Coffee Break
|
|
|
1540
|
Hatch-Waxman Act: Balancing Innovation and Affordable Drugs
Randall R. Rader, Chief Judge (Ret.), U.S. Court of Appeals for the Federal Circuit
|
|
|
1615
|
Hot Issues and Growing Trend of Pharmaceutical Patent Litigation in China--From a Perspective of Judicial Trial
Yunchuan Zhou, Of Counsel, Jones Day; Former IP Judge at the Supreme People's Court of China
Xiangjian Ying, SVP, IPHOUSE; Former Judge at Zhejiang Provincial Higher People's Court
|
|
|
1650
|
Closing Remark
|
|
|
|
|
|
Organizing Committee
Endorser
Co-Organizer
Sponsor
|